Staphylococcus aureus infections in hemodialysis: What a nephrologist should know

Clinical Journal of the American Society of Nephrology

Volumn 4, Issue 8, 2009, Pages 1388-1400

  Vandecasteele, Stefaan J ^a   Boelaert, Johan R ^a   De Vriese, An S ^a  

^a AZ Sint Jan Brugge Oostende AV ^*  (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BACITRACIN; BETA LACTAM ANTIBIOTIC; CEFAZOLIN; CEFTAROLINE; CEFTOBIPROLE; CEPHALOSPORIN DERIVATIVE; CITRATE SODIUM; CLINDAMYCIN; CLOXACILLIN; COTRIMOXAZOLE; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DICLOXACILLIN; DOXYCYCLINE; EDETIC ACID; GENTAMICIN; HEPARIN; LINEZOLID; METICILLIN; MINOCYCLINE; ORITAVANCIN; OXACILLIN; RIFAMPICIN; STAPHYLOCOCCUS VACCINE; TELAVANCIN; TIGECYCLINE; UNINDEXED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT;

ABDOMINAL INFECTION; ARTHRALGIA; BACTEREMIA; BACTERIAL COLONIZATION; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; DISTRIBUTION VOLUME; DRUG BIOAVAILABILITY; DRUG HALF LIFE; FOREIGN BODY; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; LOADING DRUG DOSE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MORBIDITY; MORTALITY; MYALGIA; NEPHROLOGIST; NEPHROTOXICITY; OTOTOXICITY; PATHOGENESIS; PNEUMONIA; REVIEW; RHABDOMYOLYSIS; SEPTICEMIA; SKIN INFECTION; STAPHYLOCOCCUS INFECTION; THROMBOPHLEBITIS; WOUND INFECTION; BLOOD VESSEL PROSTHESIS; BLOOD VESSEL TRANSPLANTATION; CATHETER INFECTION; CENTRAL VENOUS CATHETERIZATION; HETEROZYGOTE; INDWELLING CATHETER; INFECTION; INSTRUMENTATION; MICROBIOLOGY; MULTIDRUG RESISTANCE; NEPHROLOGY; PATHOGENICITY; PRACTICE GUIDELINE; RECURRENT DISEASE; RENAL REPLACEMENT THERAPY; RISK ASSESSMENT; RISK FACTOR; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; BLOOD VESSEL PROSTHESIS; BLOOD VESSEL PROSTHESIS IMPLANTATION; CARRIER STATE; CATHETER-RELATED INFECTIONS; CATHETERIZATION, CENTRAL VENOUS; CATHETERS, INDWELLING; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; NEPHROLOGY; PRACTICE GUIDELINES AS TOPIC; PROSTHESIS-RELATED INFECTIONS; RECURRENCE; RENAL DIALYSIS; RISK ASSESSMENT; RISK FACTORS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME;

EID: 70349911903     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.01590309     Document Type: Review

References (169)

1. Wulf MW, Tiemersma E, Kluytmans J, Bogaers D, Leenders AC, Jansen MW, Berkhout J, Ruijters E, Haverkate D, Isken M, Voss A: MRSA carriage in healthcare personnel in contact with farm animals. J Hosp Infect 70: 186-190, 2008
2. Lowy FD: Staphylococcus aureus infections. N Engl J Med 339: 520-532, 1998
3. Fattom AI, Horwith G, Fuller S, Propst M, Naso R: Development of StaphVAX, a polysaccharide conjugate vaccine against S. aureus infection: From the lab bench to phase III clinical trials. Vaccine 22: 880-887, 2004
4. von Eiff C, Taylor KL, Mellmann A, Fattom AI, Friedrich AW, Peters G, Becker K: Distribution of capsular and surface polysaccharide serotypes of Staphylococcus aureus. Diagn Microbiol Infect Dis 58: 297-302, 2007
5. Verdier I, Durand G, Bes M, Taylor KL, Lina G, Vandenesch F, Fattom AI, Etienne J: Identification of the capsular polysaccharides in Staphylococcus aureus clinical isolates by PCR and agglutination tests. J Clin Microbiol 45: 725-729, 2007
6. Roghmann M, Taylor KL, Gupte A, Zhan M, Johnson JA, Cross A, Edelman R, Fattom AI: Epidemiology of capsular and surface polysaccharide in Staphylococcus aureus infections complicated by bacteraemia. J Hosp Infect 59: 27-32, 2005
7. Marr KA: Staphylococcus aureus bacteremia in patients undergoing hemodialysis. Semin Dial 13: 23-29, 2000
8. Costerton JW, Stewart PS, Greenberg EP: Bacterial biofilms: A common cause of persistent infections. Science 284: 1318-1322, 1999
9. Stewart PS, Costerton JW: Antibiotic resistance of bacteria in biofilms. Lancet 358: 135-138, 2001
10. Ishani A, Collins AJ, Herzog CA, Foley RN: Septicemia, access and cardiovascular disease in dialysis patients: The USRDS Wave 2 study. Kidney Int 68: 311-318, 2005
11. Lewis K: Riddle of biofilm resistance. Antimicrob Agents Chemother 45: 999-1007, 2001
12. Lewis K: Persister cells and the riddle of biofilm survival. Biochemistry (Mosc) 70: 267-274, 2005
13. Watnick P, Kolter R: Biofilm, city of microbes. J Bacteriol 182: 2675-2679, 2000
14. Vandecasteele SJ, Peetermans WE, Carbonez A, Van Eldere J: Metabolic activity of Staphylococcus epidermidis is high during initial and low during late experimental foreign-body infection. J Bacteriol 186: 2236-2239, 2004
15. Vandecasteele SJ, Peetermans WE, Merckx R, Van Eldere J: Expression of biofilm-associated genes in Staphylococcus epidermidis during in vitro and in vivo foreign body infections. J Infect Dis 188: 730-737, 2003
16. Xu KD, McFeters GA, Stewart PS: Biofilm resistance to antimicrobial agents. Microbiology 146: 547-549, 2000
17. Chuard C, Lucet JC, Rohner P, Herrmann M, Auckenthaler R, Waldvogel FA, Lew DP: Resistance of Staphylococcus aureus recovered from infected foreign body in vivo to killing by antimicrobials. J Infect Dis 163: 1369-1373, 1991
18. Pesanti EL: Immunologic defects and vaccination in patients with chronic renal failure. Infect Dis Clin North Am 15: 813-832, 2001
19. Vanholder R, Ringoir S: Infectious morbidity and defects of phagocytic function in end-stage renal disease: A review. J Am Soc Nephrol 3: 1541-1554, 1993
20. Descamps-Latscha B, Jungers P, Witko-Sarsat V: Immune system dysregulation in uremia: Role of oxidative stress. Blood Purif 20: 481-484, 2002
21. Boelaert JR, Daneels RF, Schurgers ML, Matthys EG, Gordts BZ, Van Landuyt HW: Iron overload in haemodialysis patients increases the risk of bacteraemia: A prospective study. Nephrol Dial Transplant 5: 130-134, 1990
22. Zimmerli W, Lew PD, Waldvogel FA: Pathogenesis of foreign body infection: Evidence for a local granulocyte defect. J Clin Invest 73: 1191-1200, 1984
23. VandenBergh MF, Yzerman EP, van Belkum A, Boelens HA, Sijmons M, Verbrugh HA: Follow-up of Staphylococcus aureus nasal carriage after 8 years: Redefining the persistent carrier state. J Clin Microbiol 37: 3133-3140, 1999
24. Wertheim HF, Melles DC, Vos MC, van Leeuwen W, van Belkum A, Verbrugh HA, Nouwen JL: The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect Dis 5: 751-762, 2005
25. Graham PL III, Lin SX, Larson EL: A U.S. population-based survey of Staphylococcus aureus colonization. Ann Intern Med 144: 318-325, 2006
26. von Eiff C, Becker K, Machka K, Stammer H, Peters G: Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group. N Engl J Med 344: 11-16, 2001
27. Nouwen JL, Ott A, Kluytmans-Vandenbergh MF, Boelens HA, Hofman A, van Belkum A, Verbrugh HA: Predicting the Staphylococcus aureus nasal carrier state: Derivation and validation of a "culture rule." Clin Infect Dis 39: 806-811, 2004
28. Dancer SJ: Importance of the environment in methicillin-resistant Staphylococcus aureus acquisition: The case for hospital cleaning. Lancet Infect Dis 8: 101-113, 2008
29. Wertheim HF, Vos MC, Ott A, van Belkum A, Voss A, Kluytmans JA, van Keulen PH, Vandenbroucke-Grauls CM, Meester MH, Verbrugh HA: Risk and outcome of nosocomial Staphylococcus aureus bacteraemia in nasal carriers versus non-carriers. Lancet 364: 703-705, 2004
30. Boelaert JR, Van Landuyt HW, De Baere YA, Deruyter MM, Daneels RF, Schurgers ML, Matthys EG, Gordts BZ: Staphylococcus aureus infections in haemodialysis patients: Pathophysiology and use of nasal mupirocin for prevention. J Chemother 7[Suppl 3]: 49-53, 1995
31. Chow JW, Yu VL: Staphylococcus aureus nasal carriage in hemodialysis patients: Its role in infection and approaches to prophylaxis. Arch Intern Med 149: 1258-1262, 1989
32. Yu VL, Goetz A, Wagener M, Smith PB, Rihs JD, Hanchett J, Zuravleff JJ: Staphylococcus aureus nasal carriage and infection in patients on hemodialysis: Efficacy of antibiotic prophylaxis. N Engl J Med 315: 91-96, 1986
33. Kaplowitz LG, Comstock JA, Landwehr DM, Dalton HP, Mayhall CG: Prospective study of microbial colonization of the nose and skin and infection of the vascular access site in hemodialysis patients. J Clin Microbiol 26: 1257-1262, 1988
34. Boelaert JR, Van Landuyt HW, Gordts BZ, De Baere YA, Messer SA, Herwaldt LA: Nasal and cutaneous carriage of Staphylococcus aureus in hemodialysis patients: The effect of nasal mupirocin. Infect Control Hosp Epidemiol 17: 809-811, 1996
35. Ena J, Boelaert JR, Boyken LD, Van Landuyt HW, Godard CA, Herwaldt LA: Epidemiology of Staphylococcus aureus infections in patients on hemodialysis. Infect Control Hosp Epidemiol 15: 78-81, 1994
36. Bloembergen WE, Port FK: Epidemiological perspective on infections in chronic dialysis patients. Adv Ren Replace Ther 3: 201-207, 1996
37. Nassar GM, Ayus JC: Infectious complications of the hemodialysis access. Kidney Int 60: 1-13, 2001
38. Johnson DW, Dent H, Hawley CM, McDonald SP, Rosman JB, Brown FG, Bannister KM, Wiggins KJ: Associations of dialysis modality and infectious mortality in incident dialysis patients in Australia and New Zealand. Am J Kidney Dis 53: 290-297, 2009
39. Laupland KB, Gregson DB, Zygun DA, Doig CJ, Mortis G, Church DL: Severe bloodstream infections: A population-based assessment. Crit Care Med 32: 992-997, 2004
40. Sarnak MJ, Jaber BL: Mortality caused by sepsis in patients with end-stage renal disease compared with the general population. Kidney Int 58: 1758-1764, 2000
41. Kaplowitz LG, Comstock JA, Landwehr DM, Dalton HP, Mayhall CG: A prospective study of infections in hemodialysis patients: Patient hygiene and other risk factors for infection. Infect Control Hosp Epidemiol 9: 534-541, 1988
42. Bonomo RA, Rice D, Whalen C, Linn D, Eckstein E, Shlaes DM: Risk factors associated with permanent access-site infections in chronic hemodialysis patients. Infect Control Hosp Epidemiol 18: 757-761, 1997
43. Hoen B, Paul-Dauphin A, Hestin D, Kessler M: EPIBACDIAL: A multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol 9: 869-876, 1998
44. Diskin CJ, Stokes TJ, Dansby LM, Radcliff L, Carter TB: Is systemic heparin a risk factor for catheter-related sepsis in dialysis patients? An evaluation of various biofilm and traditional risk factors. Nephron Clin Pract 107: c128-c132, 2007
45. Teehan GS, Bahdouch D, Ruthazer R, Balakrishnan VS, Snydman DR, Jaber BL: Iron storage indices: Novel predictors of bacteremia in hemodialysis patients initiating intravenous iron therapy. Clin Infect Dis 38: 1090-1094, 2004
46. Kessler M, Hoen B, Mayeux D, Hestin D, Fontenaille C: Bacteremia in patients on chronic hemodialysis: A multicenter prospective survey. Nephron 64: 95-100, 1993
47. Marr KA, Kong L, Fowler VG, Gopal A, Sexton DJ, Conlon PJ, Corey GR: Incidence and outcome of Staphylococcus aureus bacteremia in hemodialysis patients. Kidney Int 54: 1684-1689, 1998
48. Taylor G, Gravel D, Johnston L, Embil J, Holton D, Paton S: Incidence of bloodstream infection in multicenter inception cohorts of hemodialysis patients. Am J Infect Control 32: 155-160, 2004
49. Taylor G, Gravel D, Johnston L, Embil J, Holton D, Paton S: Prospective surveillance for primary bloodstream infections occurring in Canadian hemodialysis units. Infect Control Hosp Epidemiol 23: 716-720, 2002
50. Stevenson KB, Hannah EL, Lowder CA, Adcox MJ, Davidson RL, Mallea MC, Narasimhan N, Wagnild JP: Epidemiology of hemodialysis vascular access infections from longitudinal infection surveillance data: Predicting the impact of NKF-DOQI clinical practice guidelines for vascular access. Am J Kidney Dis 39: 549-555, 2002
51. Engemann JJ, Friedman JY, Reed SD, Griffiths RI, Szczech LA, Kaye KS, Stryjewski ME, Reller LB, Schulman KA, Corey GR, Fowler VG Jr: Clinical outcomes and costs due to Staphylococcus aureus bacteremia among patients receiving long-term hemodialysis. Infect Control Hosp Epidemiol 26: 534-539, 2005
52. Inrig JK, Reed SD, Szczech LA, Engemann JJ, Friedman JY, Corey GR, Schulman KA, Reller LB, Fowler VG Jr: Relationship between clinical outcomes and vascular access type among hemodialysis patients with Staphylococcus aureus bacteremia. Clin J Am Soc Nephrol 1: 518-524, 2006
53. Abbott KC, Agodoa LY: Hospitalizations for bacterial endocarditis after initiation of chronic dialysis in the United States. Nephron 91: 203-209, 2002
54. Shroff GR, Skeans M, Herzog CA: Outcomes of renal transplant and waiting list patients with bacterial endocarditis in the United States. Nephrol Dial Transplant 23: 2381-2385: 2008
55. Kamalakannan D, Pai RM, Johnson LB, Gardin JM, Saravolatz LD: Epidemiology and clinical outcomes of infective endocarditis in hemodialysis patients. Ann Thorac Surg 83: 2081-2086, 2007
56. Mylotte JM, Tayara A: Staphylococcus aureus bacteremia: Predictors of 30-day mortality in a large cohort. Clin Infect Dis 31: 1170-1174, 2000
57. Romero-Vivas J, Rubio M, Fernandez C, Picazo JJ: Mortality associated with nosocomial bacteremia due to methicillin-resistant Staphylococcus aureus. Clin Infect Dis 21: 1417-1423, 1995
58. Chang FY, MacDonald BB, Peacock JE Jr, Musher DM, Triplett P, Mylotte JM, O'Donnell A, Wagener MM, Yu VL: A prospective multicenter study of Staphylococcus aureus bacteremia: Incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin resistance. Medicine (Baltimore) 82: 322-332, 2003
59. Fowler VG Jr, Olsen MK, Corey GR, Woods CW, Cabell CH, Reller LB, Cheng AC, Dudley T, Oddone EZ: Clinical identifiers of complicated Staphylococcus aureus bacteremia. Arch Intern Med 163: 2066-2072, 2003
60. Pfaller MA, Jones RN, Doern GV, Kugler K: Bacterial pathogens isolated from patients with bloodstream infection: Frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997). Antimicrob Agents Chemother 42: 1762-1770, 1998
61. Danese MD, Griffiths RI, Dylan M, Yu HT, Dubois R, Nissenson AR: Mortality differences among organisms causing septicemia in hemodialysis patients. Hemodial Int 10: 56-62, 2006
62. Quarles LD, Rutsky EA, Rostand SG: Staphylococcus aureus bacteremia in patients on chronic hemodialysis. Am J Kidney Dis 6: 412-419, 1985
63. Fluck R, Rao R, van Schalkwyk D, Ansell D, Feest T: The UK Vascular Access Survey: Follow-up data and repeat survey (chapter 5). Nephrol Dial Transplant 22[Suppl 7]: vii51-vii57, 2007
64. Lentino JR, Baddour LM, Wray M, Wong ES, Yu VL: Staphylococcus aureus and other bacteremias in hemodialysis patients: Antibiotic therapy and surgical removal of access site. Infection 28: 355-360, 2000
65. Tokars JI, Miller ER, Stein G: New national surveillance system for hemodialysis-associated infections: Initial results. Am J Infect Control 30: 288-295, 2002
66. Sedlacek M, Gemery JM, Cheung AL, Bayer AS, Remillard BD: Aspirin treatment is associated with a significantly decreased risk of Staphylococcus aureus bacteremia in hemodialysis patients with tunneled catheters. Am J Kidney Dis 49: 401-408, 2007
67. Kovalik EC, Raymond JR, Albers FJ, Berkoben M, Butterly DW, Montella B, Conlon PJ: A clustering of epidural abscesses in chronic hemodialysis patients: Risks of salvaging access catheters in cases of infection. J Am Soc Nephrol 7: 2264-2267, 1996
68. Obrador GT, Levenson DJ: Spinal epidural abscess in hemodialysis patients: Report of three cases and review of the literature. Am J Kidney Dis 27: 75-83, 1996
69. Johnson LB, Jose J, Yousif F, Pawlak J, Saravolatz LD: Prevalence of colonization with community-associated methicillin-resistant Staphylococcus aureus among end-stage renal disease patients and healthcare workers. Infect Control Hosp Epidemiol 30: 4-8, 2009
70. Lederer SR, Riedelsdorf G, Schiffl H: Nasal carriage of methicillin-resistant Staphylococcus aureus: The prevalence, patients at risk and the effect of elimination on outcomes among outclinic haemodialysis patients. Eur J Med Res 12: 284-288, 2007
71. Lu PL, Tsai JC, Chiu YW, Chang FY, Chen YW, Hsiao CF, Siu LK: Methicillin-resistant Staphylococcus aureus carriage, infection and transmission in dialysis patients, healthcare workers and their family members. Nephrol Dial Transplant 23: 1659-1665, 2008
72. Shorr AF: Epidemiology of staphylococcal resistance. Clin Infect Dis 45[Suppl 3]: S171-S176, 2007
73. Moellering RC Jr: Current treatment options for community-acquired methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis 46: 1032-1037, 2008
74. Invasive methicillin-resistant Staphylococcus aureus infections among dialysis patients-United States, 2005. MMWR Morb Mortal Wkly Rep 56: 197-199, 2007
75. Harbarth S, Rutschmann O, Sudre P, Pittet D: Impact of methicillin resistance on the outcome of patients with bacteremia caused by Staphylococcus aureus. Arch Intern Med 158: 182-189, 1998
76. Soriano A, Martinez JA, Mensa J, Marco F, Almela M, Moreno-Martinez A, Sanchez F, Munoz I, Jimenez de Anta MT, Soriano E: Pathogenic significance of methicillin resistance for patients with Staphylococcus aureus bacteremia. Clin Infect Dis 30: 368-373, 2000
77. McClelland RS, Fowler VG Jr, Sanders LL, Gottlieb G, Kong LK, Sexton DJ, Schmader K, Lanclos KD, Corey R: Staphylococcus aureus bacteremia among elderly vs younger adult patients: Comparison of clinical features and mortality. Arch Intern Med 159: 1244-1247, 1999
78. Selvey LA, Whitby M, Johnson B: Nosocomial methicillin-resistant Staphylococcus aureus bacteremia: Is it any worse than nosocomial methicillin-sensitive Staphylococcus aureus bacteremia? Infect Control Hosp Epidemiol 21: 645-648, 2000
79. Boucher HW, Sakoulas G: Perspectives on daptomycin resistance, with emphasis on resistance in Staphylococcus aureus. Clin Infect Dis 45: 601-608, 2007
80. Maclayton DO, Suda KJ, Coval KA, York CB, Garey KW: Case-control study of the relationship between MRSA bacteremia with a vancomycin MIC of 2 microg/mL and risk factors, costs, and outcomes in inpatients undergoing hemodialysis. Clin Ther 28: 1208-1216, 2006
81. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A: High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: Efficacy and toxicity. Arch Intern Med 166: 2138-2144, 2006
82. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM: Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 42: 2398-2402, 2004
83. Tenover FC, Moellering RC Jr: The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis 44: 1208-1215, 2007
84. Leonard SN, Rybak MJ: Evaluation of vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus and heterogeneously vancomycin-intermediate S. aureus in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations. J Antimicrob Chemother 63: 155-160, 2009
85. Jones RN: Microbiological features of vancomycin in the 21st century: Minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin Infect Dis 42[Suppl 1]: S13-S24, 2006
86. Cosgrove SE, Fowler VG Jr: Management of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 46[Suppl 5]: S386-S393, 2008
87. Sievert DM, Rudrik JT, Patel JB, McDonald LC, Wilkins MJ, Hageman JC: Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006. Clin Infect Dis 46: 668-674, 2008
88. Greiner W, Rasch A, Kohler D, Salzberger B, Fatkenheuer G, Leidig M: Clinical outcome and costs of nosocomial and community-acquired Staphylococcus aureus bloodstream infection in haemodialysis patients. Clin Microbiol Infect 13: 264-268, 2007
89. Raad I, Costerton W, Sabharwal U, Sacilowski M, Anaissie E, Bodey GP: Ultrastructural analysis of indwelling vascular catheters: A quantitative relationship between luminal colonization and duration of placement. J Infect Dis 168: 400-407, 1993
90. Saad TF: Bacteremia associated with tunneled, cuffed hemodialysis catheters. Am J Kidney Dis 34: 1114-1124, 1999
91. Nissenson AR, Dylan ML, Griffiths RI, Yu HT, Dean BB, Danese MD, Dubois RW: Clinical and economic outcomes of Staphylococcus aureus septicemia in ESRD patients receiving hemodialysis. Am J Kidney Dis 46: 301-308, 2005
92. Stryjewski ME, Szczech LA, Benjamin DK Jr, Inrig JK, Kanafani ZA, Engemann JJ, Chu VH, Joyce MJ, Reller LB, Corey GR, Fowler VG Jr: Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin Infect Dis 44: 190-196, 2007
93. Marr KA, Sexton DJ, Conlon PJ, Corey GR, Schwab SJ, Kirkland KB: Catheter-related bacteremia and outcome of attempted catheter salvage in patients undergoing hemodialysis. Ann Intern Med 127: 275-280, 1997
94. Golper TA, Schulman G, D'Agata EM: Indications for vancomycin in dialysis patients. Semin Dial 13: 389-392, 2000
95. Maya ID, Carlton D, Estrada E, Allon M: Treatment of dialysis catheter-related Staphylococcus aureus bacteremia with an antibiotic lock: A quality improvement report. Am J Kidney Dis 50: 289-295, 2007
96. Fowler VG Jr, Kong LK, Corey GR, Gottlieb GS, McClelland RS, Sexton DJ, Gesty-Palmer D, Harrell LJ: Recurrent Staphylococcus aureus bacteremia: Pulsed-field gel electrophoresis findings in 29 patients. J Infect Dis 179: 1157-1161, 1999
97. Watanakunakorn C: Mode of action and in-vitro activity of vancomycin. J Antimicrob Chemother 14[Suppl D]: 7-18, 1984
98. Rybak M, Lomaestro B, Rotschafer JC, Moellering R Jr, Craig W, Billeter M, Dalovisio JR, Levine DP: Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 66: 82-98, 2009
99. Pallotta KE, Manley HJ: Vancomycin use in patients requiring hemodialysis: A literature review. Semin Dial 21: 63-70, 2008
100. Baddour LM, Wilson WR, Bayer AS, Fowler VG Jr, Bolger AF, Levison ME, Ferrieri P, Gerber MA, Tani LY, Gewitz MH, Tong DC, Steckelberg JM, Baltimore RS, Shulman ST, Burns JC, Falace DA, Newburger JW, Pallasch TJ, Takahashi M, Taubert KA: Infective endocarditis: Diagnosis, antimicrobial therapy, and management of complications-A statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 111: e394-e434, 2005
101. Giesbrecht P, Kersten T, Maidhof H, Wecke J: Staphylococcal cell wall: Morphogenesis and fatal variations in the presence of penicillin. Microbiol Mol Biol Rev 62: 1371-1414, 1998
102. Quinn EL, Pohlod D, Madhavan T, Burch K, Fisher E, Cox F: Clinical experiences with cefazolin and other cephalosporins in bacterial endocarditis. J Infect Dis 128[Suppl]: S386-S389, 1973
103. Madhavan T, Quinn EL, Freimer E, Fisher EJ, Cox F, Burch K, Pohlod D: Clinical studies of cefazolin and comparison with other cephalosporins. Antimicrob Agents Chemother 4: 525-531, 1973
104. Marx MA, Frye RF, Matzke GR, Golper TA: Cefazolin as empiric therapy in hemodialysis-related infections: Efficacy and blood concentrations. Am J Kidney Dis 32: 410-414, 1998
105. Sowinski KM, Mueller BA, Grabe DW, Manley HJ, Frye RF, Bailie GR, Marx MA: Cefazolin dialytic clearance by high-efficiency and high-flux hemodialyzers. Am J Kidney Dis 37: 766-776, 2001
106. Marchaim D, Lazarovitch Z, Efrati S, Dishy V, Weissgarten J, Boldur I, Zaidenstein R: Serious consequences to the use of cephalosporins as the first line of antimicrobial therapy administered in hemodialysis units. Nephron Clin Pract 101: c58-c64, 2005
107. LaPlante KL, Rybak MJ: Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 48: 4665-4672, 2004
108. Apellaniz G, Valdes M, Perez R, Martin F, Soria F, Garcia A, Gomez J, Vicente T: Comparison of the effectiveness of various antibiotics in the treatment of methicillin-susceptible Staphylococcus aureus experimental infective endocarditis. J Chemother 3: 91-97, 1991
109. Small PM, Chambers HF: Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother 34: 1227-1231, 1990
110. Chang FY, Peacock JE Jr, Musher DM, Triplett P, Mac-Donald BB, Mylotte JM, O'Donnell A, Wagener MM, Yu VL: Staphylococcus aureus bacteremia: Recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore) 82: 333-339, 2003
111. Gonzalez C, Rubio M, Romero-Vivas J, Gonzalez M, Picazo JJ: Bacteremic pneumonia due to Staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis 29: 1171-1177, 1999
112. Gentry CA, Rodvold KA, Novak RM, Hershow RC, Naderer OJ: Retrospective evaluation of therapies for Staphylococcus aureus endocarditis. Pharmacotherapy 17: 990-997, 1997
113. Fortun J, Navas E, Martinez-Beltran J, Perez-Molina J, Martin-Davila P, Guerrero A, Moreno S: Short-course therapy for right-side endocarditis due to Staphylococcus aureus in drug abusers: Cloxacillin versus glycopeptides in combination with gentamicin. Clin Infect Dis 33: 120-125, 2001
114. Laupland KB, Ross T, Gregson DB: Staphylococcus aureus bloodstream infections: Risk factors, outcomes, and the influence of methicillin resistance in Calgary, Canada, 2000-2006. J Infect Dis 198: 336-343, 2008
115. Fogel MA, Nussbaum PB, Feintzeig ID, Hunt WA, Gavin JP, Kim RC: Cefazolin in chronic hemodialysis patients: A safe, effective alternative to vancomycin. Am J Kidney Dis 32: 401-409, 1998
116. Roghmann MC: Predicting methicillin resistance and the effect of inadequate empiric therapy on survival in patients with Staphylococcus aureus bacteremia. Arch Intern Med 160: 1001-1004, 2000
117. Soriano A, Marco F, Martinez JA, Pisos E, Almela M, Dimova VP, Alamo D, Ortega M, Lopez J, Mensa J: Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 46: 193-200, 2008
118. Fowler VG Jr, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, Levine DP, Chambers HF, Tally FP, Vigliani GA, Cabell CH, Link AS, DeMeyer I, Filler SG, Zervos M, Cook P, Parsonnet J, Bernstein JM, Price CS, Forrest GN, Fatkenheuer G, Gareca M, Rehm SJ, Brodt HR, Tice A, Cosgrove SE: Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 355: 653-665, 2006
119. Salzer W: Antimicrobial-resistant gram-positive bacteria in PD peritonitis and the newer antibiotics used to treat them. Perit Dial Int 25: 313-319, 2005
120. Lalani T, Boucher HW, Cosgrove SE, Fowler VG, Kanafani ZA, Vigliani GA, Campion M, Abrutyn E, Levine DP, Price CS, Rehm SJ, Corey GR, Karchmer AW: Outcomes with daptomycin versus standard therapy for osteoarticular infections associated with Staphylococcus aureus bacteraemia. J Antimicrob Chemother 61: 177-182, 2008
121. Silverman JA, Mortin LI, Vanpraagh AD, Li T, Alder J: Inhibition of daptomycin by pulmonary surfactant: In vitro modeling and clinical impact. J Infect Dis 191: 2149-2152, 2005
122. Moellering RC: Linezolid: The first oxazolidinone antimicrobial. Ann Intern Med 138: 135-142, 2003
123. Micek ST: Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 45[Suppl 3]: S184-S190, 2007
124. Shorr AF, Kunkel MJ, Kollef M: Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: Pooled analysis of randomized studies. J Antimicrob Chemother 56: 923-929, 2005
125. Lentino JR, Narita M, Yu VL: New antimicrobial agents as therapy for resistant gram-positive cocci. Eur J Clin Microbiol Infect Dis 27: 3-15, 2008
126. De Vriese AS, Coster RV, Smet J, Seneca S, Lovering A, Van Haute LL, Vanopdenbosch LJ, Martin JJ, Groote CC, Vandecasteele S, Boelaert JR: Linezolid-induced inhibition of mitochondrial protein synthesis. Clin Infect Dis 42: 1111-1117, 2006
127. Kaka AS, Rueda AM, Shelburne SA III, Hulten K, Hamill RJ, Musher DM: Bactericidal activity of orally available agents against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 58: 680-683, 2006
128. Stryjewski ME, Chambers HF: Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus. Clin Infect Dis 46[Suppl 5]: S368-S377, 2008
129. Markowitz N, Quinn EL, Saravolatz LD: Trimethoprimsulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med 117: 390-398, 1992
130. Mendes RE, Sader HS, Deshpande L, Jones RN: Antimicrobial activity of tigecycline against community-acquired methicillin-resistant Staphylococcus aureus isolates recovered from North American medical centers. Diagn Microbiol Infect Dis 60: 433-436, 2008
131. Biedenbach DJ, Bell JM, Sader HS, Turnidge JD, Jones RN: Activities of dalbavancin tested against a worldwide collection of 81,673 Gram-positive bacterial isolates. Antimicrob Agents Chemother 53: 1260-1263, 2009
132. Leonard SN, Cheung CM, Rybak MJ: Activities of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated and hospital-associated methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 52: 2974-2976, 2008
133. Shinefield H, Black S, Fattom A, Horwith G, Rasgon S, Ordonez J, Yeoh H, Law D, Robbins JB, Schneerson R, Muenz L, Fuller S, Johnson J, Fireman B, Alcorn H, Naso R: Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med 346: 491-496, 2002
134. Shanks RM, Sargent JL, Martinez RM, Graber ML, O'Toole GA: Catheter lock solutions influence staphylococcal biofilm formation on abiotic surfaces. Nephrol Dial Transplant 21: 2247-2255, 2006
135. Nori US, Manoharan A, Yee J, Besarab A: Comparison of low-dose gentamicin with minocycline as catheter lock solutions in the prevention of catheter-related bacteremia. Am J Kidney Dis 48: 596-605, 2006
136. McIntyre CW, Hulme LJ, Taal M, Fluck RJ: Locking of tunneled hemodialysis catheters with gentamicin and heparin. Kidney Int 66: 801-805, 2004
137. Weijmer MC, van den Dorpel MA, Van de Ven PJ, ter Wee PM, van Geelen JA, Groeneveld JO, van Jaarsveld BC, Koopmans MG, le Poole CY, Schrander-Van der Meer AM, Siegert CE, Stas KJ: Randomized, clinical trial comparison of trisodium citrate 30% and heparin as catheter-locking solution in hemodialysis patients. J Am Soc Nephrol 16: 2769-2777, 2005
138. Dogra GK, Herson H, Hutchison B, Irish AB, Heath CH, Golledge C, Luxton G, Moody H: Prevention of tunneled hemodialysis catheter-related infections using catheter-restricted filling with gentamicin and citrate: A randomized controlled study. J Am Soc Nephrol 13: 2133-2139, 2002
139. Betjes MG, van Agteren M: Prevention of dialysis catheter-related sepsis with a citrate-taurolidine-containing lock solution. Nephrol Dial Transplant 19: 1546-1551, 2004
140. Kim SH, Song KI, Chang JW, Kim SB, Sung SA, Jo SK, Cho WY, Kim HK: Prevention of uncuffed hemodialysis catheter-related bacteremia using an antibiotic lock technique: A prospective, randomized clinical trial. Kidney Int 69: 161-164, 2006
141. Saxena AK, Panhotra BR, Sundaram DS, Al Hafiz A, Naguib M, Venkateshappa CK, Abu-Oun BA, Hussain SM, Al Ghamdi AA: Tunneled catheters' outcome optimization among diabetics on dialysis through antibiotic-lock placement. Kidney Int 70: 1629-1635, 2006
142. Jaffer Y, Selby NM, Taal MW, Fluck RJ, McIntyre CW: A meta-analysis of hemodialysis catheter locking solutions in the prevention of catheter-related infection. Am J Kidney Dis 51: 233-241, 2008
143. III. NKF-K/DOQI clinical practice guidelines for vascular access: Update 2000. Am J Kidney Dis 37: S137-S181, 2001
144. Goetz AM, Wagener MM, Miller JM, Muder RR: Risk of infection due to central venous catheters: Effect of site of placement and catheter type. Infect Control Hosp Epidemiol 19: 842-845, 1998
145. Heard SO, Wagle M, Vijayakumar E, McLean S, Brueggemann A, Napolitano LM, Edwards LP, O'Connell FM, Puyana JC, Doern GV: Influence of triple-lumen central venous catheters coated with chlorhexidine and silver sulfadiazine on the incidence of catheter-related bacteremia. Arch Intern Med 158: 81-87, 1998
146. Merrer J, De Jonghe B, Golliot F, Lefrant JY, Raffy B, Barre E, Rigaud JP, Casciani D, Misset B, Bosquet C, Outin H, Brun-Buisson C, Nitenberg G: Complications of femoral and subclavian venous catheterization in critically ill patients: A randomized controlled trial. JAMA 286: 700-707, 2001
147. Parienti JJ, Thirion M, Megarbane B, Souweine B, Ouchikhe A, Polito A, Forel JM, Marque S, Misset B, Airapetian N, Daurel C, Mira JP, Ramakers M, du Cheyron D, Le Coutour X, Daubin C, Charbonneau P: Femoral vs jugular venous catheterization and risk of nosocomial events in adults requiring acute renal replacement therapy: A randomized controlled trial. JAMA 299: 2413-2422, 2008
148. O'grady NP, Alexander M, Dellinger EP, Gerberding JL, Heard SO, Maki DG, Masur H, McCormick RD, Mermel LA, Pearson ML, Raad II, Randolph A, Weinstein RA: Guidelines for the prevention of intravascular catheter-related infections. Am J Infect Control 30: 476-489, 2002
149. Tal MG, Ni N: Selecting optimal hemodialysis catheters: Material, design, advanced features, and preferences. Tech Vasc Interv Radiol 11: 186-191, 2008
150. Pittet D, Hugonnet S, Harbarth S, Mourouga P, Sauvan V, Touveneau S, Perneger TV: Effectiveness of a hospital-wide programme to improve compliance with hand hygiene. Infection Control Programme. Lancet 356: 1307-1312, 2000
151. Hu KK, Lipsky BA, Veenstra DL, Saint S: Using maximal sterile barriers to prevent central venous catheter-related infection: A systematic evidence-based review. Am J Infect Control 32: 142-146, 2004
152. Maki DG, Ringer M: Evaluation of dressing regimens for prevention of infection with peripheral intravenous catheters. Gauze, a transparent polyurethane dressing, and an iodophor-transparent dressing. JAMA 258: 2396-2403, 1987
153. Maki DG, Ringer M, Alvarado CJ: Prospective randomised trial of povidone-iodine, alcohol, and chlorhexidine for prevention of infection associated with central venous and arterial catheters. Lancet 338: 339-343, 1991
154. Block C, Robenshtok E, Simhon A, Shapiro M: Evaluation of chlorhexidine and povidone iodine activity against methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus faecalis using a surface test. J Hosp Infect 46: 147-152, 2000
155. Gilbert RE, Harden M: Effectiveness of impregnated central venous catheters for catheter related blood stream infection: A systematic review. Curr Opin Infect Dis 21: 235-245, 2008
156. Kupferwasser LI, Yeaman MR, Nast CC, Kupferwasser D, Xiong YQ, Palma M, Cheung AL, Bayer AS: Salicylic acid attenuates virulence in endovascular infections by targeting global regulatory pathways in Staphylococcus aureus. J Clin Invest 112:222-233, 2003
157. Palma M, Bayer A, Kupferwasser LI, Joska T, Yeaman MR, Cheung A: Salicylic acid activates sigma factor B by rsbU-dependent and -independent mechanisms. J Bacteriol 188: 5896-5903, 2006
158. Farr B, Mandell GL: Rifampin. Med Clin North Am 66: 157-168, 1982
159. Falagas ME, Fragoulis KN, Bliziotis IA: Oral rifampin for prevention of S. aureus carriage-related infections in patients with renal failure: A meta-analysis of randomized controlled trials. Nephrol Dial Transplant 21: 2536-2542, 2006
160. Baddour LM, Wilson WR, Bayer AS, Fowler VG Jr, Bolger AF, Levison ME, Ferrieri P, Gerber MA, Tani LY, Gewitz MH, Tong DC, Steckelberg JM, Baltimore RS, Shulman ST, Burns JC, Falace DA, Newburger JW, Pallasch TJ, Takahashi M, Taubert KA: Infective endocarditis: Diagnosis, antimicrobial therapy, and management of complications-A statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 111: e394-e434, 2005
161. Levine DP, Fromm BS, Reddy BR: Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 115: 674-680, 1991
162. Gemmell CG, Edwards DI, Fraise AP, Gould FK, Ridgway GL, Warren RE: Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. J Antimicrob Chemother 57: 589-608, 2006
163. Zimmerli W, Widmer AF, Blatter M, Frei R, Ochsner PE: Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: A randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA 279: 1537-1541, 1998
164. Zimmerli W, Trampuz A, Ochsner PE: Prosthetic-joint infections. N Engl J Med 351: 1645-1654, 2004
165. Levin A, Mason AJ, Jindal KK, Fong IW, Goldstein MB: Prevention of hemodialysis subclavian vein catheter infections by topical povidone-iodine. Kidney Int 40: 934-938, 1991
166. Johnson DW, MacGinley R, Kay TD, Hawley CM, Campbell SB, Isbel NM, Hollett P: A randomized controlled trial of topical exit site mupirocin application in patients with tunnelled, cuffed haemodialysis catheters. Nephrol Dial Transplant 17: 1802-1807, 2002
167. Johnson DW, van Eps C, Mudge DW, Wiggins KJ, Armstrong K, Hawley CM, Campbell SB, Isbel NM, Nimmo GR, Gibbs H: Randomized, controlled trial of topical exit-site application of honey (Medihoney) versus mupirocin for the prevention of catheter-associated infections in hemodialysis patients. J Am Soc Nephrol 16: 1456-1462, 2005
168. Boelaert JR, De Smedt RA, De Baere YA, Godard CA, Matthys EG, Schurgers ML, Daneels RF, Gordts BZ, Van Landuyt HW: The influence of calcium mupirocin nasal ointment on the incidence of Staphylococcus aureus infections in haemodialysis patients. Nephrol Dial Transplant 4: 278-281, 1989
169. Boelaert JR, Van Landuyt HW, Godard CA, Daneels RF, Schurgers ML, Matthys EG, De Baere YA, Gheyle DW, Gordts BZ, Herwaldt LA: Nasal mupirocin ointment decreases the incidence of Staphylococcus aureus bacteraemias in haemodialysis patients. Nephrol Dial Transplant 8: 235-239, 1993